上海复星医药（集团）股份有限公司 关于控股子公司药品注册申请获 受理的公告

Overview - Shanghai Fosun Pharmaceutical (Group) Co., Ltd. announced that its subsidiary, Shanghai Chaohui Pharmaceutical Co., Ltd., has had its drug registration application for Benzocaine Gel accepted by the National Medical Products Administration [2] Drug Information and Research Status - The drug is a chemical product independently developed by the group, intended for transdermal local anesthesia, suitable for adults and infants over one month old [3] - As of December 2025, the cumulative R&D investment for this drug is approximately RMB 7.19 million (unaudited) [4] - According to the latest IQVIA CHPA data, the estimated sales for Benzocaine Gel in mainland China (excluding Hong Kong, Macau, and Taiwan) is approximately RMB 443 million in 2024 [4] Impact on the Company - The acceptance of the drug registration application will not have a significant impact on the group's current performance, as commercial production is contingent upon passing GMP compliance checks and obtaining drug registration approval [5] - The specific sales performance of the drug post-launch may be influenced by factors such as medication demand, market competition, and sales channels, which carry a high degree of uncertainty [5]